论文部分内容阅读
目的探讨丹参酮ⅡA磺酸钠联合依达拉奉治疗急性脑梗死的临床疗效及安全性。方法选取100例急性脑梗死患者,随机数字表法分为两组,对照组患者(50例)给予依达拉奉治疗,观察组患者(50例)给予丹参酮ⅡA磺酸钠联合依达拉奉治疗,均治疗14 d。观察并记录两组患者治疗后1个月的疗效,治疗前后ESS评分、SF-36评分及治疗期间不良反应情况。结果治疗后,观察组有效率为90.0%,对照组有效率为72.0%,观察组治疗有效率明显高于对照组(P<0.05)。与治疗前相比,治疗后两组ESS评分均明显增加(P<0.05),且观察组在治疗3、7、14 d的ESS评分均明显高于对照组(P<0.05)。治疗前两组SF-36各项得分相比,差异没有统计学意义;治疗后,两组SF-36各项得分均明显升高(P<0.05),且观察组在生理功能、生理职能及精神健康上的评分高于对照组(P<0.05)。治疗期间,两组不良反应率无明显差异。结论丹参酮ⅡA磺酸钠联合依达拉奉对急性脑梗死具有较好的治疗作用,能改善患者神经功能,提高患者生活质量,用药具有安全性,值得临床推广使用。
Objective To investigate the clinical efficacy and safety of tanshinone Ⅱ A sulfonate combined with edaravone in the treatment of acute cerebral infarction. Methods A total of 100 patients with acute cerebral infarction were selected and randomized into two groups. Fifty patients in the control group were treated with edaravone. The patients in the observation group (50 patients) were given tanshinone Ⅱ A sulfonate combined with edaravone Treatment, were treated for 14 days. The curative effect of one month after treatment, ESS score before and after treatment, SF-36 score and adverse reaction during treatment were observed and recorded. Results After treatment, the effective rate was 90.0% in the observation group and 72.0% in the control group, and the effective rate in the observation group was significantly higher than that in the control group (P <0.05). ESS scores of both groups were significantly increased (P <0.05), and the ESS scores of the observation group at 3, 7 and 14 days were significantly higher than those of the control group (P <0.05). The scores of SF-36 in the two groups before treatment were not significantly different. After treatment, SF-36 scores of both groups were significantly increased (P <0.05), and the observation group had significant differences in physiological function, physiological function and Mental health score higher than the control group (P <0.05). During treatment, there was no significant difference in adverse reactions between the two groups. Conclusion Sodium tanshinone Ⅱ A sulfonate combined with edaravone has a good therapeutic effect on acute cerebral infarction. It can improve the neurological function and improve the quality of life of patients. The medication is safe and worthy of clinical application.